Moreover, we have demonstrated that soluble SULF2 is increased in blood from early stage NSCLC patients thus, providing the first evidence of soluble blood SULF2 as a potential biomarker for early detection of NSCLC. The gene discussed is SULF2; the disease is non-small cell lung carcinoma.